779 reports of this reaction
1.6% of all ENALAPRIL MALEATE reports
#15 most reported adverse reaction
MYOCARDIAL INFARCTION is the #15 most commonly reported adverse reaction for ENALAPRIL MALEATE, manufactured by Bausch Health US LLC. There are 779 FDA adverse event reports linking ENALAPRIL MALEATE to MYOCARDIAL INFARCTION. This represents approximately 1.6% of all 48,429 adverse event reports for this drug.
Patients taking ENALAPRIL MALEATE who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for ENALAPRIL MALEATE, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for ENALAPRIL MALEATE:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 779 FDA reports for ENALAPRIL MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 1.6% of all adverse event reports for ENALAPRIL MALEATE, making it a notable side effect.
If you experience myocardial infarction while taking ENALAPRIL MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.